U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures ...

Detailed price information for Rapport Therapeutics Inc (RAPP-Q) from The Globe and Mail including charting and trades.

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarte ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, ...

-- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission -- -- Remains on track to submit NAUTILUS PMA Supplement to ...

Epilepsy is a common neurological disorder that affects millions of people worldwide. Characterized primarily by seizures, epilepsy can present in a variety of ways depending on the individual and the ...

“It’s all about the brain,” said Jennifer DeWolfe, D.O., professor in the UAB Department of Neurology. “Seizure manifestations are stereotyped, so the same symptoms occur with each seizure that ...

Children referred to a first seizure clinic (FSC) see a neurologist epilepsy specialist within one week, according to a study presented at the annual meeting of the American Epilepsy Society, held ...